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Background: Methylation of the p16 promoter is one of the most frequent mechanisms of gene inactivation; its
incidence is extremely variable according to the type of tumor involved. Our purpose was to analyze the
hypermethylation of the p16 promoter in laryngeal squamous cell carcinomas (LSCC), salivary gland (SG) tumors and
in colorectal cancer (CRC), to detect any possible association with the clinicopathological features and to determine
the prognostic significance of the p16 gene in the tumors analyzed.
Patients and methods: The hypermethylation of the p16 promoter was prospectively analyzed, by MSP, in
a consecutive series of 64 locally advanced LSCC patients, in a consecutive series of 33 SG tumor patients and in
a consecutive series of 66 sporadic CRC patients.
Results: Hypermethylation was observed in 9% of the LSCC cases, in all cases of SG cancer and in 21% of the CRC
cases. No significant association was observed between p16 hypermethylation and clinicopathological variables in all
the tissue samples analyzed. Moreover at univariate analysis p16 mutations were not independently related at disease
relapse and death in LSCC and CRC.
Conclusions: The results of this study suggest that the lack of p16 function could happen in advanced stage of SG
tumors.
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introduction
DNA methylation is an epigenetic phenomenon that affects
both normal DNA function and interaction with proteins [1]. In
normal conditions, methylation is a control mechanism for the
tissue expression of specific genes and their contemporaneous
silencing in the cells of different tissues [2]. This perfect
epigenetic balance of normal cells is altered when the cells
become tumoral [2]. Aberrations in DNA methylation patterns
are, in fact, now recognized as a hallmark of human cancer.
DNA methylation of promoter-associated CpG islands is an
alternate mechanism to mutation in silencing gene function,
and affects tumor-suppressor genes such as p16 and RB1,
growth and differentiation controlling genes such as ER, and
many other genes involved in the apoptotic pathways, in DNA
repair, in the cell cycle, in cell adhesion, and so on [3]. One
of the most common alterations, occurring early in
tumorigenesis, is the hypermethylation of the oncosuppressor
gene promoters [2]. A great many studies have reported that
during the carcinogenetic process, hypermethylation often
occurs in order to silence one or both alleles [4, 5]. Methylation
of the p16 promoter is one of the most frequent mechanisms
of gene inactivation; its incidence is extremely variable
according to the type of tumor involved. P16 inhibits the
cycline D1-Cdk 4/6 complex, which is responsible for the
phosphorylation of the Rb protein, thus bringing about a block
in the cell cycle in phase G1 [6].
In laryngeal squamous cell carcinomas (LSCC) p16
alterations (deletion, mutation or down-regulation caused by
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the promoter hypermethylation) appear to be one the
mechanisms implicated in neoplastic transformation and
progression [7]. It has been reported that in 22% of cases, p16 is
inactivated by mutations or deletions in homozygosis and in 7%
by promoter hypermethylation [7]. Nevertheless, the effect of
p16 promoter methylation in the development of salivary gland
(SG) carcinomas remains unclear. Furthermore, little is known
about the promoter methylation role in adenoid cystic
carcinomas (ACC) of the salivary gland.
It has been suggested that altered expressions of pRb and p16
are involved in colorectal cancer, indicating that these two
genes, either alone or combined, might be useful as markers of
an unfavorable outcome [8]. Cui et al. [9] have observed
expression loss of the gene p16 in 62% of their cases of CRC.
Moreover, several analyses of the silencing of this gene by
promoter methylation have reported different results [10–12].
The aim of this study, therefore, was to analyze the
hypermethylation of the p16 promoter in head and neck tumors
(locally-advanced LSCC and SG tumors) and in gastrointestinal
tumors (CRC), to detect any possible association with the
clinicopathological features of patients with these diseases and
finally to determine the prognostic significance of the p16 gene
in the various tumors analyzed.
patients and methods
study design
LSCC patients. A prospective study was performed on paired tumor and
normal laryngeal tissue samples from a consecutive series of 64 patients
with stage III (32 T3 N0, 4 T2 N1 and 6 T3 N1) and stage IV (8 T4 N0, 3 T4
N1, 8 N2 and 3 N3), undergoing potentially radical surgical resection for
primary tumor of larynx between April 1990 and December 1998. Briefly,
the following inclusion criteria were used: (a) electively resected primary
LSCC; (b) processing of fresh paired normal mucosa-tumor samples within
30 min after tumor removal; and (c) available DNA from normal and tumor
tissue. In order to avoid evaluator variability in the patients, all resection
specimens and microscopic slides were meticulously examined by two
independent pathologists (RMT and VM) who were not aware of the
original diagnosis or of the results of the molecular analysis. The complete
excision of the primary tumor was histologically proven by examination of
the resected margins. All tumors were histologically confirmed to be
squamous cell carcinomas. In addition, the pathologists assessed tumor site
(supraglottis, glottis, subglottis), tumor size, pathological stage, tumor grade
(histological differentiation), and the presence or absence of lymph node
metastases. Tumors were staged according to the American Joint Committee
on Cancer and graded as well (grade 1), moderately (grade 2) and poorly
(grade 3) differentiated. Lymph node involvement was evaluated clinically
and histologically without considering the number or location of nodes.
Written informed consent was obtained from all patients included in this
study. A standard questionnaire of more than 50 clinicopathologic and
research variables was available for each patient at the moment of surgery
and was maintained on a computerized data base. Postoperatively, all
patients were checked at 3-monthly intervals for the first 2 years, at 6-
monthly intervals for the next 2 years, and annually thereafter. The follow-
up program included a clinical examination, blood tests (including CEA and
SCC assays) and annual chest X-ray. Disease relapse (local recurrence or
distant metastases) was confirmed histologically where possible.
SG cancer patients. A prospective study was performed on tumor
samples from a consecutive series of 33 patients who underwent resective
surgery for primary operable SG tumor at the Department of Oncology,
University of Palermo, Italy. All resection specimens and microscopic slides
were examined by two independent pathologists (RMT and VM) who were
blinded to the original diagnosis and the results of molecular analyses. The
complete excision of the primary tumor was histologically proven by
examination of the resected margins. The study material included 28 PAs,
four cystic adenocarcinomas and one carcinoma ex-pleomorphic adenoma.
Tissues were fixed in 70% ethyl alcohol and paraffin-embedded. At least
three single sections were analyzed from each paraffin-embedded tissue. One
of the sections was used for microdissection followed by mutational analysis,
while the others were used for immunohistochemistry experiments.
CRC patients. A prospective study was performed on paired tumor and
normal colon tissue samples from a consecutive series of 66 previously
untreated patients, undergoing resective surgery for primary operable
sporadic CRC at a single institution (Department of Oncology, University of
Palermo) from January 1988 to December 1992.
Briefly, none of the patients had any history of previous neoplasias,
synchronous or metachronous CRC. All tumors were histologically
confirmed to be colorectal adenocarcinomas. Patients with Dukes’ stage A
and B sporadic CRC were treated with surgery alone, whereas all the 28
patients with Dukes’ stage C received adjuvant chemotherapy with 5-FU,
leucovorin and levamisole since in the period before 1991 hardly any of the
patients had received adjuvant treatment. Patients with non-radical surgery
and/or distant metastases were treated with 5-FU and leucovorin.
Postoperatively, all patients were checked at 3-monthly intervals for the
first 2 years, at 6-monthly intervals for the next 2 years, and annually
thereafter. Written informed consent was obtained from all patients
included in the study.
tissue handling and DNA extraction
LSCC. Multiple samples (four to eight) of the primary tumor tissue were
taken from at least four different tumor areas (including the core and the
invasive edge of the tumor). The portion of primary tumor was obtained by
superficial biopsy of either the tumor bulk or the edge of the malignant ulcer
for more infiltrative cancer. All tissues were carefully trimmed to remove as
much non-neoplastic tissue as possible, avoiding the non-viable areas.
Furthermore, samples of normal mucosa (as confirmed by histology) were
taken from a macroscopically uninvolved area 2–5 cm away from the tumor
site, to be used as control for biomolecular and flow cytometric analysis. The
tissues were bisected, one half of each sample was processed for pathological
examination, and the remaining half of the sample pool was immediately
frozen and stored at 80C until analyzed. Where present, areas with a high
content of non-neoplastic cells where removed from the frozen block with
a scalpel. Genomic DNA was extracted using the QIAamp Tissue Kit
(Qiagen, Hilden, Germany) with the standard protocol from primary LSCC
and normal laryngeal specimens.
SG cancer. Sections, 5-lm, of paraffin-embedded tissue specimens,
prepared using a microtome, were mounted on the supporting Laser
Pressure Catapulting (LPC) membrane placed on the slide. The samples
were pretreated with xylene for 10 min and rehydrated using decreasing
grade alcohols (100%, 95% 50% ethanol) and H2O. The slides were then
stained with hematoxylin and eosin and dehydrated using increasing graded
alcohol. LPC was performed using a Zeiss inverted microscope PALM Laser
Micro-Beam System UV laser at 337 nm. Before performing
microdissection, 1 ll of mineral oil was placed on the samples. The areas
to be dissected were selected by means of extremely high-precision
microcuts (the specimens ranged from as little as 1 lm to 1000 lm in
diameter). LPC dissection was performed using a few shots each
of 100 lm in diameter. After catapulting, the material was removed from
the cap for genetic analysis. Genomic DNA from tumor and normal
specimens was extracted using the QIAamp Tissue Kit (Qiagen, Hilden,
Germany) following standard protocol.
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CRC. Multiple samples of the primary tumor tissue were taken from
different tumor areas (including the core and the invasive edge of the
tumor). Furthermore, multiple samples of normal mucosa (as confirmed by
histology) were taken from macroscopically uninvolved areas 20–40 cm
away from the tumor site, to be used as a control for biomolecular and flow-
cytometric analysis. The tissues were bisected; one half of each sample was
processed for pathological examination and the remaining half of the sample
pool was immediately frozen and stored at 80C until analyzed. The
adequacy of the material was checked on frozen tissue sections and only
tissue samples with more than 80% tumor content were utilized in
subsequent biomolecular analysis. Evaluation of each biomolecular was
performed independently by researchers who had no knowledge of the
clinical data regarding the samples. Genomic DNA was extracted using the
QIAamp Tissue Kit (Qiagen, Hilden, Germany) with the standard protocol
from primary CRC and normal colorectal specimens.
p16 methylation assay. One mg of genomic DNA was treated with sodium
bisulfite at 50C for 18 h using CpG genome modification kit (ONCOR,
Gaithersburg, MD). The modified DNA was amplified by PCR using specific
primers (Table 1) to distinguish methylated and unmethylated regions MD).
The amplification products were verified by 2% agarose gel electrophoresis
and ethidium bromide staining.
statistical analysis
Fisher’s exact test (StatXact Turbo, Cytel Software Corporation, Cambridge,
MA, USA) was used to evaluate the associations between biological variables.
The relationship of different prognostic variables with disease-free survival
(DFS) and overall survival (OS) was assessed univariately by means of the
Kaplan–Meier method. Survival time was calculated from the date of surgery
to the date of death (cancer-related causes) or last follow-up, with times
censored for patients dying of causes unrelated to the specific tumor. DFS
was measured from the day of primary surgery to the date of the first relapse
(locoregional or metastatic). Significant differences among survival curves
were checked by the log-rank test and Wilcoxon test, or a trend test where
appropriate. P values less than 0.05 were considered significant.
results
clinicopathologic variables
The LSCC study group was made up of 63 men and one woman
and the mean age was 64.5 ± 8.3 years (range 42–85 years). The
histopathological features of these patients are listed in Table 2.
The CRC series of patients comprised 32 females and 34 males
with a median age of 69 ± 11.9 years (range 35–87). The
histopathological features of these patients are listed in Table 3.
methylation status of the p16 gene
For LSCC patients, hypermethylation of the p16 gene promoter
was assessed in 9% (six of 64) of analyzed tumors. For SG cancer
patients, the analysis of the methylation status of the p16INK4a
gene promoter revealed that 14% (four of 28) of the PAs
examined showed aberrant methylation within the CpG island.
Furthermore, in all five cases of carcinoma examined, we found
hypermethylation of the p16INK4a promoter. For CRC patients,
14 of the 66 colorectal cancer patients (21%) showed
a hypermethylation status of the p16INK4A gene promoter.
No significant association was observed between p16
hypermethylation and clinicopathological variables in all the
tissue samples analyzed.
No significant difference were observed in relapse or death for
patients with p16 hypermethylation gene in LSCC and CRC.
discussion
The p16INK4a (CDKN2A/MTS1) putative tumor suppressor
gene encodes a cyclin dependent kinase inhibitor, which plays
an important role in the regulation of the G1/S phase cell cycle
checkpoint. A high frequency of various p16 gene alterations
was consequently observed in many primary tumors. P16 can be
inactivated by different mechanisms: homozygous deletion;
methylation of the promoter region; or point mutation [13].
Defects in the system controlling the cell cycle can lead to an
increased proliferation of cancer cells.
head and neck cancer
Hypermethylation is a fundamental mechanism for the
epigenetic inactivation of key genes in the development of head
and neck tumors [14]. It has, in fact, been observed in between
7% and 47% of HNSCCs [15–17].
LSCC
In order to investigate the molecular mechanisms responsible
for the inactivation of one of the two alleles of the p16 gene in
LSCC, we evaluated the methylational status of its promoter. In
accordance with a previous study, we found methylation of 9%;
in fact, Jares et al. in a series of 46 LSCCs, observed a p16
hypermethylation rate of 7% [18]. This suggests that although
hypermethylation of the promoter region of the p16 gene has
been shown to be one of the major mechanisms for the
inactivation of this tumor suppressor gene [19], it may not play
such an important role in LSCC. This is in line with the finding
that hypermethylation of p16 is a selective phenomenon
depending on the tissue of origin [20, 21]. Several studies have
suggested that p16 might not be the only inactivation target in
this chromosomic region and that several other
oncosuppressors might also be involved [22]. In our own study
we did not find any association between the p16 promoter
hypermethylation and the clinicopathological features of the
patients examined. Moreover in our study no significant
differences were observed in relapse or death for patients with
p16 hypermethylation gene. Until now, according to our results,
no literature data have shown a prognostic significance of p16
hypermethylation gene in LSCC.
Table 1. PCR primers used for MSP analysis of p16 gene
Primers: sense 59/ 39 Primers: antisense 59/ 39 Anneal, C
P16M tta tta gag ggt ggg gcg gat cgc gac ccc gaa ccg cga ccg taa- 61
P16U tta tta gag ggt ggg gtg gat tgt cca ccc caa acc aca acc ata a 66
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SG cancer
Since hypermethylation is clearly extremely important in the
development of head and neck tumors, it has been decided to
analyze the p16 promoter methylation status on a group of 28
pleomorphic adenomas and five salivary gland tumors.
Hypermethylation of the p16 promoter was observed in 14% of
the pleomorphic adenomas and in all five cases of salivary gland
tumors.
A recent study of 42 cases of PA and SG cancer has shown that
p16INK4a does not present microdeletions or specific mutations
in any exons, but in 28% of cases there was methylation of the
p16INK4a promoter, which correlated with loss of mRNA
transcription [23]. Data reported in literature regarding p16
methylation are discordant, which might depend on the
different feeding habits of the patients involved in the various
studies [24].
The results reported in literature are extremely varied,
including those regarding the incidence of p16INK4a promoter
methylation in SG tumors, which range from 11% to 47%.
[25, 26]. The high percentage of our own results might depend
on the fact that we used the microdissection laser technique,
which made it possible to select only tumoral cells. Furthermore,
reported data often regard studies conducted on Oriental
populations, where this type of neoplasia is more common and
the results obtained in these cases might therefore also be
affected by different feeding habits.
colorectal cancer
Methylation of the CpG islands associated with transcriptional
silencing, seems to be common in tumors of the colon [27]. In
particular, a specific CpG methylator phenotype (CIMP) has
been proposed that seems to be responsible for colorectal cancer
progression [28]. This model is explained by the identification
in the genome of sites that are preferentially methylated in
tumors (MINT loci). In addiction to this, CRC with CIMP have
been shown to have methylation of know tumor suppressor
gene such as p16 [29]. In particular, a literature review has
shown a frequency of p16 hypermethylation in sporadic CRC
between 20% and 50% [30–33]. In the present study,
a frequency of p16 hypermethylation in 14 of 66 (21%) CRC
patients has been identified. Finally, much evidence has shown
that tumors with CIMP phenotype are associated with specific
clinicopathological characteristics: a poor differentiation,
a higher stage and a tumor in proximal colon. Unfortunately, in
this study, we did not identify an association between the
epigenetic alteration in p16 gene and the clinicopathological
characteristics of CRC patients. The literature data of the
prognostic significance of p16 hypermethylation are
controversial. In fact, while San-Casla et al. [34] did not find any
prognostic role of p16 hypermethylation in CRC progression,
both in term of DFS and OS, other authors show that p16
hypermethylation predicts shorter survival [35, 36]. All of these
discordant data might be due to several factors, such as tumor
storage method (fresh/frozen tissue and paraffin-embedded
blocks), the different techniques used for assessing the
methylation status of p16 gene (MSP, Southern blott, RFLP,
etc.), tumoral heterogeneity, or the specific features of the
patient cohorts included in the study, such as histopathologic
staging, grading, histological type of tumor.
In conclusion, the results of this study do not support the
hypothesis that the p16 hypermethylation gene could have
a predominant role in tumorigenesis pathway. Even so, we have
identified a major frequency of p16 methylation in all the
salivary gland tumors suggesting that the lack of p16 function
Table 2. Histopathology characteristic of LSCC patients
Tumor site
Supraglottis 30
Glottis 30
Subglottis 4
Histological grade
G1 20
G2 31
G3 13
Size
T2 7
T3 39
T4 18
Stage
III 42
IV 22
Node status
Node negative 40
Node nositive 24
Table 3. Histopathological characteristics of CRC tumors
Tumor site
Proximal 8
Distal 8
Rectum 50
Histological grade
G1 5
G2 49
G3 12
Size
£5 cm 41
>5 cm 25
Dukes’ stage
A 16
B 19
C 30
D 1
Node status
Node negative 52
Node positive 14
Figure 2. P16INK4a analysis using MSP in 4 LSCC patients. The presence
of an amplified band indicates that the site is unmethylated (U) or
methylated (M); ct: unmethylated (U) or methylated (M) Control; I: 100
bp ladder.
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could happen in advanced stage of these specific tumors.
Additional studies and larger samples are needed before our
conclusions are validated.
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